CAR T-Cell Therapy in Israel

In Israel, CAR T cell therapy represents a promising frontier in cancer treatment. Pioneered by Israeli researchers, this groundbreaking immunotherapy utilizes genetically engineered T cells to target cancer cells with precision.

Institutions like Sheba Medical Center and Tel Aviv Sourasky Medical Center are leading the charge, offering hope to patients with refractory leukemia and lymphoma.

With ongoing research and clinical trials, Israel continues to push the boundaries of CAR T cell therapy, offering new avenues for combating cancer.

CAR T cell therapy has become a new way to treat many types of cancer, and Israel has made a lot of progress in this area. Israeli medical centres have been on the cutting edge of CAR T cell therapy study and development, giving patients with blood cancers that haven’t responded to other treatments hope. Israeli scientists have helped create and make CAR T cells, which has improved their effectiveness and safety. CAR T cell therapy has been used successfully on patients at Israeli hospitals like Sheba Medical Centre, Tel Aviv hospital, and Hadassah Medical Centre. This has led to amazing remissions and higher mortality rates. Israel is still very important to the progress of CAR T cell treatment, which gives cancer patients all over the world new hope.

CAR T-Cell therapy in Israel – Recent advances

CAR T cell therapy, a new type of immunotherapy that is making a big splash in the field of cancer care, is a good example. Famous hospitals and study centres in Israel have been at the forefront of developing and using this new therapy, giving hope to people with different types of cancer. CAR T-Cell therapy in Israel is now available in multiple hospitals.

The Sheba Medical Center is one of the best places in Israel to get CAR T cell treatment. It set up the Center for Cellular Immunotherapy, which is in charge of making and giving out personalized CAR T cell therapy. Sheba’s team of experts has made amazing progress in helping people with blood cancers like leukaemia and lymphoma. Patients from all over the world who want advanced treatments come to them because of their knowledge and state-of-the-art facilities.

Another important place is the Hadassah Medical Centre in Jerusalem, which has been doing a lot of study into CAR T cell therapy. Their main goal has been to help kids with acute lymphoblastic leukaemia (ALL) that has come back or doesn’t respond to treatment. The success stories from Hadassah have given hope to families going through hard times, as CAR T cell therapy could be a lifeline for those with few treatment choices.

In recent years, CAR T cell treatment has made a lot of progress in Israel. Researchers have been looking for ways to make the treatments work better and help more people. One of these is the use of CAR T cells with two different targets. By going after multiple antigens at once, this method aims to make the therapy more successful and reduce the risk of antigen escape, which is when cancer cells avoid being recognised by CAR T cells.

Also, Israeli scientists have been looking into new ways to treat solid tumours, which have been harder to treat than haematological diseases in the past. Researchers at the Tel Aviv Sourasky Medical Centre have been testing CAR T cells that have been changed to make them produce extra molecules that can make them better at killing solid tumours. Early results are looking good, which gives people hope that CAR T cell therapy could be a big step forward in treating solid tumours.

CAR T cell therapy has changed the way cancer is treated, giving patients new options and new hope. In Israel, the best hospitals and study centres keep pushing the limits of this therapy, trying to make it work better and help more people. As research moves forward, CAR T cell treatment is likely to become more important in Israel and around the world in the fight against cancer.

Why choose Israel for CAR T-Cell therapy?

Cost and availability

CAR T-Cell therapy cost in Israel is significantly lower than that in countries like US, UK, Australia, Japan, Korea and Singapore. CAR T-Cell therapy in Israel may cost just $ 75-100,000 USD. Israel has a comparatively high availability of CAR T cell therapy. Israel has set up centres and hospitals that treat different kinds of cancer with CAR-T cell treatment. These institutions have been doing this kind of treatment for a long time and have access to the infrastructure and tools they need. When choosing where to get CAR-T cell therapy, it’s important to think about availability.

Shorter wait time

When CAR T-cell products are made in-house, they have the same success rate as commercial CAR made by pharma, with almost no manufacturing mistakes. Managing the whole process on-site means that the time from leukapheresis to CAR administration can be cut down to about 10 days. This means that the patient doesn’t have to go through bridging therapy, which is linked to better results. In short overall treatment time reduces only to 30 days as compared to 60-75 days in other countries.

Advanced medical expertise

Israel is known for its excellent medical studies and new ideas. The country has made important advances to immunotherapy, including CAR-T cell therapy. Israeli doctors and nurses are often the first to develop and use new treatments, making sure that their patients get the best care possible.

How to apply for CAR T-Cell therapy in Israel?

Send your medical reports to info@cancerfax.com or WhatsApp them to +1-213 789-56-55 or Call +91 96 1588 1588. Send following reports for opinion and estimate:

1) Medical summary

2) Latest blood reports

3) Biopsy

4) Latest PET Scan

5) Bone marrow biopsy (If available)

6) Any other relevant reports and scans

Once our team receives your medical reports, we analyze them and send it to hospitals that are performing CAR T-Cell therapy with that type of cancer and marker. We send reports to the concerned specialist and get his opinion. We also get estimate from the hospital on complete treatment. This helps you in planning for the entire treatment duration.

Once you decide to visit for the treatment, we arrange for medical visa letter and other necessary documents from the hospital. We also help and guide you in applying for medical visa to the Israeli embassy. Once visa is ready we help and guide you in preparing for travel and flight tickets. We also arrange for your hotel and guest house, if required in Israel. Upon arrival in the city of treatment our representative will welcome you at the airport.

Our representative will arrange for doctor appointment and complete the necessary registration formalities for you. He will also help you with your hospital admission and other local help and support that are required. After the treatment is over we will arrange for your follow up consultation with the treating doctor.

Top hospitals for CAR T-Cell therapy in Israel

Sheba Medical Center

CAR T-cell therapy, which is done at Sheba Hospital in Tel Aviv, Israel, is a big step forward in treating cancer. It gives people with certain types of blood cancers hope. In Hebrew, Sheba Hospital is called Tel HaShomer. It is the biggest hospital in Israel and a leader in the area of CAR T-cell therapy.
Sheba Hospital has cutting-edge tools and technologies to help with CAR T-cell therapy. The hospital has special units that are set up with the latest technology for making cells. This makes sure that each patient’s CAR-modified T cells are made quickly and safely. Also, the team of doctors and nurses at Sheba Hospital has a lot of experience running clinical trials and studying CAR T-cell therapy, which helps this field keep getting better.

Tel-Aviv Sourasky Medical Center

The Tel Aviv Sourasky Medical Centre (Ichilov Hospital) is a place where you can get a new kind of treatment called car T-cell therapy. In this new treatment, the patient’s own T cells are changed genetically so that they can recognise and attack cancer cells. The patient’s body is then filled with these cells that have been changed in a lab. There, they can find and kill cancer cells. The Car T-cell therapy programme at the Tel Aviv Sourasky Medical Centre is run by a team of doctors and immunotherapy experts with a lot of experience. Patients with different kinds of cancer can have hope with this advanced treatment choice, which gives them a personalized and effective way to fight the disease.

Hadassah Medical Center

The Hadassah Medical Centre in Jerusalem is at the heart of a new way to treat cancer called Car T-cell therapy. Car T-cell therapy changes and activates T cells so they can recognise and fight cancer cells. It does this by using the power of the patient’s own immune system. The skilled group of doctors and experts at Hadassah work together to provide this cutting-edge therapy. Hadassah Medical Centre gives people with different kinds of cancer hope and better outcomes with its cutting-edge equipment and dedication to new ideas. Car T-cell therapy at Hadassah is a shining example of progress in the field of oncology. It gives patients choices for personalized and targeted treatment.

Top doctor’s for CAR T-Cell therapy in Israel

Take expert second opinion on CAR T-Cell therapy infusion from best CAR T-Cell therapy experts in Israel.

Profile: Arnon Nagler, served for many years as a director of both the Division of Hematology and the Bone Marrow Transplantation and Cord Blood Bank at the Chaim Sheba Medical Center, and Professor of Medicine at The Tel Aviv University, Israel.

Profile: Prof. Amos Toren is the Director of the Pediatric Hemato-Oncology and BMT Division, certified in Pediatrics, General Hematology and Pediatric Hemato-Oncology. He served as the Head of the division of Hematology at Sackler School of Medicine Tel-Aviv University for 2 terms.

Profile: Prof. Dina Ben-Yehuda, head of the Hadassah Medical Organization’s Department of Hematology, has been named Dean of the Hadassah-Hebrew University Faculty of Medicine–the first woman to have the position.

What is the cost of CAR T-Cell therapy in Israel?

Cost of CAR T-Cell therapy in Israel starts from $ 75,000 USD depending upon the brand of CAR T chosen. For local home grown CAR T therapy cost will be around \$ 80,000 USD whereas for therapies like Kymeriah and Breyanzi cost may go up to \$ 470,000 USD. Car T-cell therapy costs can vary in Israel based on a number of things, such as the medical centre, the type of cancer being treated, and the health of the patient. Car T-cell therapy is a complicated and highly specialized treatment that includes changing genes and giving each patient their own care. Because of this, it is an expensive procedure. In general, the costs of Car T-cell therapy include the process of genetic engineering, hospitalisation, fees for medical staff, and tracking after the treatment. Patients should talk to their healthcare providers and insurance companies to find out what the costs might be and what kinds of financial help or insurance benefits are available.

What is CAR T-Cell therapy?

CAR-T-Cell- therapy in China

Chimeric antigen receptor T-cell therapy, often known as CAR T-cell therapy, is a ground-breaking immunotherapy that has completely changed the way that cancer is treated. It gives patients with certain cancers hope that were previously seen as incurable or with few therapeutic alternatives.

The treatment entails using a patient’s own immune cells—more specifically, T cells—and lab-modifying them to improve their capacity to detect and destroy cancer cells. To do this, the T cells are given a chimeric antigen receptor (CAR), which gives them the ability to target particular proteins, or antigens, on the surface of cancer cells.

T cells from the patient are first removed, and they are then genetically modified to express the CAR. In the laboratory, these altered cells are multiplied to produce a sizable population of CAR T cells, which are then put back into the patient’s bloodstream.

As soon as they are inside the body, CAR T cells find cancer cells that express the desired antigen, attach to them, and trigger a potent immune response. The CAR T cells that have been activated proliferate and conduct a focused attack on the cancer cells, killing them.

How does CAR T-Cell therapy work?

When used to treat some blood malignancies like acute lymphoblastic leukaemia (ALL) and specific forms of lymphoma, CAR T-cell therapy has shown exceptional results. It has produced notable response rates and in some patients, even long-lasting remissions.

CAR T-cell therapy, however, is a sophisticated and unique therapeutic method that might have risks and adverse effects. Cytokine release syndrome (CRS), a widespread immunological reaction that can result in flu-like symptoms and, in extreme situations, organ failure, may be experienced by certain people. There have also been reports of neurological adverse effects, however they are frequently curable.

Despite these difficulties, CAR T-cell therapy is a significant advancement in the fight against cancer and shows great potential for the future. Current studies are focused on enhancing its efficacy and safety profile as well as extending its uses to different cancer types. CAR T-cell therapy has the ability to change the face of cancer treatment and give patients everywhere new hope with further advancements.

This type of therapy involves modifying the patient’s T cells, an immune cell type, in the lab so they will bind to and kill cancer cells. A tube transports blood from a vein in the patient’s arm to an apheresis device (not shown), which extracts white blood cells, including T cells, and returns the remaining blood to the patient.

The T cells are then genetically modified in the lab to contain the gene for a unique receptor known as a chimeric antigen receptor (CAR). The CAR T cells are multiplied in a lab before being infused into the patient in large numbers. The antigen on the cancer cells can be recognized by CAR T cells, which then kill the cancer cells.

Procedure

The CAR-T therapy procedure, which takes a few weeks, involves multiple steps:

T cells are extracted from your blood using a tube that is placed into an arm vein. This takes a couple of hours.

T cells are transported to a facility where they undergo genetic modification to become CAR-T cells. Two to three weeks pass throughout this.

CAR-T cells are reintroduced into your bloodstream through a drip. This requires several hours.

CAR-T cells target and eliminate cancer cells throughout the body. After receiving CAR-T therapy, you will be closely watched.

What type of cancer cells can be treated with CAR-T Cell Therapy?

Only patients with adult B-cell non-lymphoma Hodgkin’s or pediatric acute lymphoblastic leukemia who have already tried two unsuccessful conventional therapies can currently use CAR T-cell therapy products that have received FDA approval. However, CAR T-cell therapy is now being tested in clinical studies as a first or second-line treatment for adult lymphoma and pediatric acute lymphoblastic leukemia. Recently, some of the studies have shown remarkable successes in cases of solid tumors too like glioblastoma, gliomas, liver cancer, lung cancer, GI cancer, pancreatic cancer and oral cancers.

To conclude

This represents a significant advancement in the management of leukemia and B-cell lymphoma. Additionally, it gives hope to those whose lives had previously been predicted to last only six months. Now that we have identified mechanisms of resistance and created more techniques to combat them, the future appears to be much more promising.

Get in touch with our highly experienced healthcare providers here at CancerFax for a free consultation to work out a suitable care plan for your healthcare needs. Please send your medical reports to info@cancerfax.com or WhatsApp to +1 213 789 56 55.

What are the advantages of CAR-T Cell Therapy?

The main benefit is that CAR T-cell therapy only requires a single infusion and often only requires two weeks of inpatient care. Patients with non-Hodgkin lymphoma and pediatric leukemia who have just been diagnosed, on the other hand, typically need chemotherapy for at least six months or more.

The advantages of CAR T-cell therapy, which is actually a living medication, can persist for many years. If and when a relapse occurs, the cells will still be able to identify and target cancer cells because they can survive in the body for an extended period of time.

Although the information is still developing, 42% of adult lymphoma patients who underwent CD19 CAR T-cell treatment were still in remission after 15 months. And after six months, two-thirds of patients with pediatric acute lymphoblastic leukemia were still in remission. Unfortunately, these patients had exceedingly aggressive tumors that weren’t successfully treated using traditional standards of care.

What type of patients would be good recipients of the CAR-T Cell Therapy?

Patients between the age of 3 Years to 70 Years have been tried with CAR T-Cell therapy for different type of blood cancers and has been found to be very effective. Many centers have claimed success rates of more than 80%. The optimum candidate for CAR T-cell therapy at this time is a juvenile with acute lymphoblastic leukemia or an adult with severe B-cell lymphoma who has already had two lines of ineffective therapy.

Before the end of 2017, there was no accepted standard of care for patients who had already gone through two lines of therapy without experiencing remission. The only FDA-approved treatment that has so far proven to be significantly beneficial for these patients is CAR T-cell therapy.

How effective is CAR-T Cell therapy?

CAR T-cell therapy has been very effective in treating some types of blood cancer, like acute lymphoblastic leukaemia (ALL) and non-Hodgkin lymphoma. In clinical trials, the response rates have been very good, and a lot of patients have gone into full remission. In some cases, people who had tried every other medicine had long-lasting remissions or even possible cures.

One of the best things about CAR T-cell treatment is that it targets the right cells. The CAR receptors that have been added to the T cells can find specific marks on cancer cells. This makes it possible to give targeted treatment. This targeted method hurts healthy cells as little as possible and lowers the risk of side effects that come with traditional treatments like chemotherapy.

But it’s important to keep in mind that CAR T-cell therapy is still a new area that is still changing. Researchers and doctors are working hard to solve problems like the high cost, the possibility of serious side effects, and the fact that it only works for some types of cancer.

In the end, CAR T-cell therapy has shown to be a very successful way to treat some types of blood cancer. Even though it is a promising and powerful method, more study and clinical trials are needed to improve it and find new ways to use it. CAR T-cell therapy could change how cancer is treated and make things better for people all over the world if it keeps getting better.

Inclusion & exclusion criteria

Inclusion criteria for CAR T-cell therapy:

1. Patients with CD19+ B-cell Lymphoma(At least 2 prior combination chemotherapy regimens)

2. To be aged 3 to 75 years

3. ECOG score ≤2

4. Women of childbearing potential must have a urine pregnancy test taken and proven negative prior to the treatment. All patients agree to use reliable methods of contraception during the trial period and until follow-up for the last time.

Exclusion criteria for CAR T-cell therapy:

1. Intracranial hypertension or unconsciousness

2. Respiratory failure

3. Disseminated intravascular coagulation

4. Hematosepsis or Uncontrolled active infection

5. Uncontrolled diabetes.

CAR T-Cell therapies approved by USFDA

B-cell precursor acute lymphoblastic leukemia, relapsed or refractory diffuse large B-cell lymphoma

Complete response rate (CR): >90%

Target: CD19

Price: $475,000

Approval time: August 30, 2017

Relapsed or refractory diffuse large B-cell lymphoma, relapsed or refractory follicular cell lymphoma

Non-Hodgkin’s lymphoma Complete response rate (CR): 51%

Target: CD19

Price: $373,000

Approval time: 2017 October 18

Relapsed or refractory diffuse large B-cell lymphoma

Mantle cell lymphoma Complete response rate (CR): 67%

Target: CD19

Price: $373,000

Approved time: October 18, 2017

Relapsed or refractory diffuse large B-cell lymphoma

Complete response rate (CR): 54%

Target: CD19
Price: $410,300

Approved time: October 18, 2017

Relapsed or Refractory Multiple Myeloma

Complete response rate: 28%

Target: CD19
Price: $419,500
Approved: October 18, 2017

What are the side effects of CAR-T Cell therapy?

Below mentioned are some of the side-effects of CAR T-Cell therapy.

Cytokine release syndrome (CRS): The most prevalent and possibly significant side effect of CAR T-cell treatment is cytokine release syndrome (CRS). The flu-like symptoms, including fever, exhaustion, headaches, and muscle pain, are brought on by the modified T cells’ production of cytokines. In extreme circumstances, CRS may result in a high temperature, hypotension, organ failure, and even potentially fatal consequences.
Neurological Toxicity: Some patients may develop neurological side effects, which can range in severity from less serious signs like mild confusion and disorientation to more serious ones like seizures, delirium, and encephalopathy. After CAR T-cell infusion, neurological toxicity frequently happens during the first week.
Cytopenias: CAR T-cell treatment can result in low blood cell counts, such as anaemia (low red blood cell count), neutropenia (low white blood cell count), and thrombocytopenia (low platelet count). Infections, bleeding, and exhaustion are among risks that can be exacerbated by these cytopenias.
Infections: The CAR T-cell therapy’s suppression of healthy immune cells increases the risk of bacterial, viral, and fungal infections. In order to prevent infections, patients may need to be closely watched and given preventive medication.
Tumour Lysis Syndrome (TLS): After CAR T-cell therapy, it’s possible in some circumstances for substantial amounts of cell contents to be released into the bloodstream due to the rapid killing of tumour cells. This may result in metabolic abnormalities, such as excessive potassium, uric acid, and phosphate levels, which may damage the kidneys and cause other problems.
Hypogammaglobulinemia: CAR T-cell treatment has the potential to decrease antibody synthesis, which could result in hypogammaglobulinemia. This might make recurrent infections more likely and call for continuing antibody replacement medication.
Organ Toxicity: CAR T-cell therapy has the potential to harm a number of organs, including the heart, lungs, liver, and kidneys. This may lead to abnormal renal function tests, respiratory issues, heart issues, and abnormal liver function tests.
Hemophagocytic lymphohistiocytosis (HLH): A rare but possibly fatal immunological disease called hemophagocytic lymphohistiocytosis (HLH) can develop as a result of CAR T-cell therapy. It involves the overactivation of immune cells, which causes serious organ damage and inflammation.
Hypotension and Fluid Retention: As a result of the cytokines that CAR T cells release, some patients may develop low blood pressure (hypotension) and fluid retention. To address these symptoms, supportive measures including intravenous fluids and drugs could be required.
Secondary Malignancies: Reports of secondary malignancies emerging following CAR T-cell therapy exist, notwithstanding their rarity. Research is currently being done on the potential for secondary malignancies and long-term hazards.

It’s important to remember that not every patient will have these side effects, and that each person’s level of sensitivity will differ. In order to minimize and minimize these potential adverse effects, the medical team closely examines patients before, during, and after CAR T-cell therapy.

Time frame

Check below the total time frame required for complete the CAR T-Cell therapy process. Although time frame depends a lot on the distance of lab from the hospital that prepared the CAR’s.

Examination & test: one week
Pre-treatment & T-Cell Collection: one week
T-Cell preparation & return: two-three weeks
1st Effectiveness analysis: three weeks
2nd Effectiveness analysis: three weeks.

Total time frame: 10-12 Weeks